Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.79 |
| ▸ | HPGD | P15428 | 6/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | AHR | P35869 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4731862 | 0.88 | KDM4E (0.80) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| SCHEMBL14014100 | 0.86 | KDM4E (0.77) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| SCHEMBL14014196 | 0.83 | KDM4E (0.85) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| SCHEMBL3284626 | 0.82 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| SCHEMBL14014215 | 0.82 | KDM4E (0.82) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| SCHEMBL3291896 | 0.82 | KDM4E (0.81) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| SCHEMBL14014187 | 0.81 | KDM4E (0.68) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| SCHEMBL14014104 | 0.81 | KDM4E (0.68) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| SCHEMBL14014213 | 0.81 | KDM4E (0.64) | KDM4EALDH1A1HPGDHSD17B10MAPK1 | |
| SCHEMBL4197477 | 0.81 | HPGD (0.74) | KDM4EALDH1A1HPGDHSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010086040-A1 | PYRAZOLO-PYRIMIDINES FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA, LTD. (BS) | 2010-08-05 | — | — | WO | claimed |
| US-20190201414-A1 | INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2019-07-04 | — | — | US | disclosed |
| US-8450368-B2 | Heme oxygenase inhibitors, screening methods for heme oxygenase inhibitors and methods of use of heme oxygenase inhibitors for antimicrobial therapy | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450368-B2 | Heme oxygenase inhibitors, screening methods for heme oxygenase inhibitors and methods of use of heme oxygenase inhibitors for antimicrobial therapy | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2013-05-28 | — | — | US | disclosed |
| WO-2010086040-A1 | PYRAZOLO-PYRIMIDINES FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA, LTD. (BS) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010086040-A1 | PYRAZOLO-PYRIMIDINES FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA, LTD. (BS) | 2010-08-05 | — | — | WO | disclosed |
| US-20100081661-A1 | HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081661-A1 | HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081661-A1 | HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY | HMOX1, HMOX2, PPOX | KDM4E 2274/4885ALDH1A1 802/4885HPGD 45/4885 |
| US-20190201414-A1 | INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION | HMOX1, HMOX2, PPOX | KDM4E 2238/4885ALDH1A1 1493/4885HPGD 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.